REST OF THE WORLD
An Imprint of quality across markets |
|
| The high-growth global generic markets are an exciting opportunity, and are estimated to reach $ 135 billion by 2015. Emerging markets are expected to grow at 3 times the growth rate for developed markets. (CSFB Pharma Far Marts, March 2010). In yet another 2010 report, IMS indicated that 17 high-performing pharmerging nations, that accounted for 16% of the total world market or US$123 billion in 2009, were about to overturn the established pharmaceutical world order and account for 58% of global growth by 2013 ( IMS Pharmerging shake up, 2010) |
|
| We are taking our speciality prescription products to select international markets. Currently we are present in markets across specific countries in South East Asia, South America, Russia, China, some countries across the Middle East. Manufacturing sites in Brazil, Mexico, Bangladesh and Hungary enhance our capability to compete as a local player. Taro strengthens this part of the business with a ready presence with dermatologicals in important international markets like Israel and Canada.. |
|
In each of the markets of our interest, specific speciality products are sold as branded generics that require a prescription. A 650- strong representative force is in place. In addition to a comprehensive range of products, several of our brands use complex technology, and at times we are the only branded generic for that product.
Our intent is to bring to customers in these markets the same products that have delivered value and quality in India. Products with complex technologies such as Lupride Depot (Lupreolide one and six months depot injection) and Lipodox (liposomal doxorubicin)..
|
|
| Click
here to view the complete product list. |
|
|
 |
|
|
|
|
|
